Twi Biotechnology, Inc

TWi Biotechnology(6610.TWO) is a late stage clinical biopharmaceutical company developing innovative therapies for rare dermatologic diseases and central nervous system (CNS) disorders. With established expertise in 505(b)(2) development, the company focuses on advancing differentiated formulations that address significant unmet medical needs using clinically validated mechanisms. Our approach is to efficiently transform proven pharmacology into value-enhanced, first-in-class therapies with optimized delivery, safety, and patient experience. By leveraging existing human data, we aim to reduce development time, cost, and clinical risk while delivering meaningful innovation to underserved patient populations. Our management team brings extensive experience across clinical development, regulatory strategy, and commercialization, having held leadership roles in global pharmaceutical and biotechnology organizations. This collective expertise supports disciplined and capital-efficient advancement of our pipeline. AC203, our lead program for rare dermatologic indications, has received U.S. FDA Orphan Drug Designation (ODD), underscoring its therapeutic potential and regulatory advantage. In parallel, we are advancing CNS programs targeting major psychiatric conditions, including areas of overlap with women’s health, further strengthening a balanced pipeline across rare and high-prevalence diseases. TWi Biotechnology combines clear therapeutic focus, proven development efficiency, and experienced leadership to advance impactful, patient-centered therapies in rare dermatologic diseases, with emerging expansion into women’s health.